Saxsons Group

NM Physician's Notes · ¹⁷⁷Lu-PSMA-617

The salivary gland is what decides how many cycles the patient gets.

VISION and PSMAfore patients received six cycles of 7.4 GBq ¹⁷⁷Lu-PSMA-617, six weeks apart. Xerostomia and bone-marrow toxicity, not tumour response, set the stopping criterion. The published trial data is anchored on n.c.a.-grade chemistry — specific activity well above 3,000 GBq/mg, Lu-177m essentially absent, radiochemical purity ≥ 99 %. This post unpacks what each spec is doing to your patient's salivary dose budget, kidney dose tail and decay-store cycle — and why a Lu-177 supply that misses any one of those numbers is not actually n.c.a., regardless of marketing.

Cumulative PSMA-617 mass across VISION

Same activity. Five-fold less cold peptide on salivary PSMA.

Cycle n.c.a. (SHINE) Carrier-added Clinical consequence
7.4 GBq × cycle 1 ~2.5 mg PSMA-617 ~12 mg PSMA-617 Cycle 1 — receptor saturation in salivary / lacrimal glands sets the xerostomia baseline
7.4 GBq × cycle 3 ~2.5 mg PSMA-617 ~12 mg PSMA-617 Cumulative cold peptide on salivary PSMA — xerostomia begins to plateau
7.4 GBq × cycle 6 ~2.5 mg PSMA-617 ~12 mg PSMA-617 End of course — cumulative cold-peptide drives the dose-limiting late toxicity ceiling
Total 6-cycle mass ~15 mg cumulative ~72 mg cumulative ~5× more cold peptide circulating systemically through the 36-week course

Source: SHINE FDA Drug Master File summary; Begum NJ et al. EJNMMI 2019 (salivary dosimetry); EANM/SNMMI PSMA-617 procedural guidelines 2023.

Spec 1 — Specific activity ≥ 3,000 GBq/mg

Cold-peptide load on salivary PSMA — why higher is unambiguously better

  • PSMA-617 (vipivotide tetraxetan) binds PSMA on prostate cancer cells — and on salivary gland and lacrimal gland epithelium, where PSMA is also expressed. The binding chemistry does not distinguish ¹⁷⁵Lu, ¹⁷⁶Lu or ¹⁷⁷Lu — cold and radioactive Lu-PSMA-617 conjugates compete for the same PSMA sites.
  • For a 7.4 GBq cycle, carrier-added Lu-177 (~600 GBq/mg) requires ~12 mg PSMA-617 to chelate the activity. SHINE-produced n.c.a. Lu-177 (≥ 3,000 GBq/mg) requires ~2.5 mg PSMA-617 — a fifth of the peptide mass at the same therapeutic activity.
  • Across the six-cycle VISION-equivalent course, cumulative PSMA-617 exposure with CA Lu-177 is ~72 mg vs ~15 mg with n.c.a. The cold peptide load at the salivary and lacrimal binding sites drives xerostomia and dry-eye severity — the published dose-limiting late toxicities in PSMA-617 therapy.
  • On post-therapy SPECT/CT, n.c.a. patients typically show higher tumour-to-salivary-gland uptake ratio. The activity actually reaching prostate metastases is less competed against by cold-peptide saturation in normal PSMA-expressing tissue.

Source: Sartor O et al. VISION NEJM 2021; Morris MJ et al. PSMAfore Lancet 2024; Begum NJ et al. EJNMMI 2019; SHINE FDA Drug Master File.

Spec 2 — Radionuclidic purity ≥ 99.9 % ¹⁷⁷Lu

Lu-177m and the long-tail kidney / salivary dose problem

  • The Ph. Eur. monograph for Lutetium-177 chloride requires ≥ 99.9 % radionuclidic purity. CA and n.c.a. supplies both pass this number at calibration. What sits inside the residual 0.1 % is completely different.
  • CA Lu-177 is produced by direct neutron capture on Lu-176. The same flux activates a side channel that produces Lu-177m — a metastable nuclear isomer with a 160-day half-life. The CA 0.1 % residual is mostly Lu-177m.
  • n.c.a. Lu-177 is produced indirectly via Yb-176(n,γ)Yb-177 → β⁻ → Lu-177. There is no production channel for Lu-177m. The n.c.a. 0.1 % residual is short-lived activation products that decay alongside the parent.
  • The VISION protocol is six cycles of 7.4 GBq, six weeks apart — a 36-week course. With CA Lu-177, every cycle deposits a small Lu-177m payload that decays at 160-day half-life. By cycle 6, cumulative Lu-177m in the patient is meaningful and contributes a long tail to renal and bone-marrow dose long after the last therapeutic ¹⁷⁷Lu has decayed.
  • EANM / SNMMI procedural guidance for ¹⁷⁷Lu-PSMA-617 sets a cumulative renal-dose ceiling (typical 23 Gy biologic-effective) and a cumulative salivary-gland-dose threshold (~30–40 Gy). Lu-177m is a hidden contribution to both ceilings. n.c.a. supply removes it. CA supply leaves it in the dose budget — sometimes silently.

Source: IAEA TECDOC-1955; EANM/SNMMI PSMA-617 procedural guidelines 2023; Kuo PH et al. ¹⁷⁷Lu-PSMA-617 outcomes by PSMA PET SUV, J Nucl Med 2022.

Spec 3 — Radiochemical purity ≥ 99 % as ¹⁷⁷LuCl₃

Only free Lu(III) chelates onto PSMA-617

  • Ph. Eur. monograph 2798 requires ≥ 99 % radiochemical purity as ¹⁷⁷LuCl₃ for the starting material. The other species formed during storage is colloidal lutetium hydroxide, Lu(OH)₃ — which forms when the dilute HCl matrix drifts toward neutral pH.
  • PSMA-617 — like every DOTA-conjugate peptide — chelates only the free Lu(III) cation. Colloidal Lu(OH)₃ is inert to the labelling reaction. A 1 % colloid fraction means 1 % of the injected activity behaves as free lutetium colloid in the patient — RES uptake in liver and spleen rather than tumour.
  • The 0.04 M HCl matrix in which n.c.a. ¹⁷⁷LuCl₃ is supplied is engineered for this exact reason. Saxsons cold-chain delivery preserves the matrix from calibration to labelling day; the radiopharmacy QC reads the labelling-yield endpoint that follows from it.
  • Below 99 % RCP, the consequences cascade: lower labelling yield, lower tumour delivery, elevated liver / spleen uptake on post-therapy SPECT/CT, and a degraded biodistribution that the dosimetry workflow has to reconcile against the prescribed cycle activity. The salivary-gland dose ceiling — already tight — gets harder to defend.

Source: Ph. Eur. monograph 2798 (Lutetium-177 chloride solution); EANM/SNMMI PSMA-617 procedural guidelines 2023.

The definition

A VISION-equivalent course requires VISION-equivalent chemistry

  • "n.c.a." names a production-route choice, not a release-certificate threshold. A CA-process Lu-177 vial can read 99.9 % RNP at calibration and still be CA — because the 0.1 % residual is Lu-177m, which the production route inevitably co-produces.
  • A genuine n.c.a. Lu-177 supply has three signatures together: production from a Yb-176 target (not a Lu-176 target), specific activity well above the CA ceiling (≥ 3,000 GBq/mg vs ~600), and Lu-177m present below routine detection limits.
  • If a supplier markets "n.c.a." but Lu-177m is detectable at the level CA grade carries, the product is CA grade. The patient gets CA-grade salivary dose tail and CA-grade kidney dose tail. The protocol is no longer working from the chemistry the VISION trial used.
  • VISION and PSMAfore patients were treated with n.c.a.-grade ¹⁷⁷Lu-PSMA-617. The salivary-gland dose limit, the six-cycle protocol cadence and the long-term safety profile published in the trials are not directly transferable to a CA-grade Lu-177 supply.

Source: Sartor O et al. VISION NEJM 2021; Morris MJ et al. PSMAfore Lancet 2024; SHINE FDA Drug Master File.

Lu-177 + PSMA-617

More for this product

Sibling posts in the ¹⁷⁷Lu-PSMA-617 family.

For Nuclear-Medicine Physician

Nuclear-Medicine Physician

PSMA PET as the patient-selection decision document

VISION eligibility, the PSMAfore line-of-therapy shift, and the salivary-gland and kidney dose ceilings that bound the six-cycle ¹⁷⁷Lu-PSMA-617 course.

Read this